Rational Pharmacotherapy in Cardiology

Advanced search

Antiarrhythmic drugs use in elderly patients. Vaughan Williams class I and II drugs

Full Text:


Use of class I antiarrhythmic drugs in the elderly is limited by their adverse drug reactions (ADRs), proarrhythmic effect (I A и I C) and high risk of drug interactions. Disopyramide use should be avoided due to its strong anticholinergic properties associated with the risk of cognitive and physical disorders and falls in the “very elderly” patients. Available data suggest that elderly patients do not have significant limitations for beta-blockers use. However to determine beta-blockers with the best benefit/risk ratio in elderly patients with co-morbidity further clinical trials are needed.

About the Authors

E. A. Ushkalova
People's Friendship University of Russia
Russian Federation
Miklukho-Maklaya ul. 6, Moscow, 117198

S. K. Zyryanov
People's Friendship University of Russia
Russian Federation
Miklukho-Maklaya ul. 6, Moscow, 117198

K. E. Zatolochina
People's Friendship University of Russia
Russian Federation
Miklukho-Maklaya ul. 6, Moscow, 117198

A. P. Pereverzev
People's Friendship University of Russia
Russian Federation
Miklukho-Maklaya ul. 6, Moscow, 117198

N. A. Chukhareva
Scientific Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Oparina ul. 4, Moscow, 117997


1. Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin 2012;8:143-64.

2. BlackmoreHL, Ozanne SE. Programming of cardiovascular disease across the life-course.J Mol Cell Cardiol 2015; 83: 122–30.

3. Takahashi K,Hayashi M, Iwasaki YK, et al. Urgent Catheter Ablation in Octogenarians with Serious Tachyarrhythmias. J Nippon Med Sch 2016;83(2):62-70.

4. Camm JA, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The task force for the management of atrial fibrillation of the European society of cardiology (ESC) Eur Heart J 2010;31:2369-429.

5. Withers KL, Wood KA, Carolan-Rees G, et al. Living on a knife edge-the daily struggle of coping with symptomatic cardiac arrhythmias. Health Qual Life Outcomes 2015;13:86.

6. Leal MA, Field ME, Page RL. Ventricular arrhythmias in the elderly: evaluation and medical management. Clin Geriatr Med 2012;28(4):665-77.

7. Chow GV, Marine JE, Fleg JL. Epidemiology of arrhythmias and conduction disorders in older adults. Clin Geriatr Med 2012;28(4):539-53.

8. Mirza M, Strunets A, Shen WK, Jahangir A. Mechanisms of arrhythmias and conduction disorders in older adults. Clin Geriatr Med 2012;28(4):555-73.

9. Go AS, Hylek EA, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18):2370-5.

10. Barrios V, Calderón A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol 2012;65(1):47-53.

11. Bulanova NA, Stazhadze LL, Alekseeva LA et al. The prevalence of atrial fibrillation in patients seen in outpatient settings. Kardiologiia 2011; 12: 29-35. In Russian (БулановаН.А., СтажадзеЛ.Л.,Алексеева Л.А и др. Распространенность фибрилляции предсердий у больных, наблюдаемых в условиях поликлиники. Кардиология 2011;12: 29-35).

12. Schwartz JB, Zipes DP. Cardiovascular disease in the elderly. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald’s heart disease-a textbook of cardiovascular medicine. 9th edition. Philadelphia: Saunders; 2011. p. 1727-56.

13. Deneer VH, van Hemel NM. Is Antiarrhythmic Treatment in the Elderly Different? A Review of the Specific Changes. Drugs Aging 2011;28(8):617-33.

14. Frishman WH, Aronow WS. Pharmacology of AntiarrhythmicDrugs in Elderly Patient. Clin Geriatr Med 2012;28(4):575-615.

15. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden CardiacDeath of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36(41):2793-867.

16. Tamargo J, Le Heuzey JY, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol 2015;71(5):549-67.

17. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993;270:1589-95.

18. Karamichalakis N, Letsas KP, Vlachos K, et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag 2015;11:555-62.

19. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-8.

20. Akiyama T, Pawitan Y, Campbell WB, et al. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. J Am Geriatr Soc 1992;40:666-67.

21. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott) 2016;149(3):139-52.

22. Cardwell K, Hughes CM, Ryan C. The Association Between Anticholinergic Medication Burden and Health Related Outcomes in the 'Oldest Old': A Systematic Review of the Literature. Drugs Aging 2015;32(10):835-48.

23. Kalus JS. Pharmacologic management of atrial fibrillation: established and emerging options. J Manag Care Pharm 2009;15(6 Suppl B):S10-8.

24. RuDusky BM. Cholestyramine therapy for quinidine-induced diarrhea. Case reports. Angiology 1997;48(2):173-6.

25. Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace 2014;16(2):162-73.

26. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel.J Am Geriatr Soc 2015;63(11):2227-46.

27. Swen JJ, Wilting I, de Goede AL, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 2008; 83: 781-7.

28. Starodubtsev AK, Kuznetsov AB. Chapter 19. Application of certain aspects of the pharmacokinetics of anti-arrhythmic drugs. In: Kukes VG, ed. Clinical Pharmacokinetics. Moscow: GEOTAR Media; 2009. pp 399-406. In Russian (Стародубцев А.К., Кузнецов А.Б. Глава 19. Прикладные аспекты фармакокинетики некоторых антиаритмических препаратов. В: Кукес В.Г., ред. Клиническая фармакокинетика. М.: ГЭОТАР-Медиа; 2009. С. 399-406).

29. Fattinger K, Vozeh S, Ha HR, et al. Population pharmacokinetics of quinidine. Br J Clin Pharmacol 1991;31(3):279-86.

30. Ehrlich C, Tsu LV. Updates in Antiarrhythmic Therapy for Atrial Fibrillation in Geriatric Patients.Consult Pharm 2015;30(2):82-91.

31. Kubesova HM, Weber P, Meluzinova H, et al. Benefits and pitfalls of cardiovascular medication in seniors. Wien Klin Wochenschr 2013;125(15-16):425-36.

32. Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2013;13:52.

33. Szentmiklosi AJ, Szentandrássy N,Hegyi B, et al. Chemistry, physiology, and pharmacology of β-adrenergic mechanisms in the heart. Why are β-blocker antiarrhythmics superior? Curr Pharm Des 2015;21(8):1030-41.

34. Olshansky B, Rosenfeld LE, Warner AL, et al. AFFIRM Investigators The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43(7):1201-8.

35. Gallagher P, O'MahonyD. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 2008;37(6):673-9.

36. O'MahonyD, O'SullivanD, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44(2):213-8.

37. Abete P, Testa G, Della-Morte D, et al. Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev 2013;18(4):529-51.

38. Hanon O. Specificities of heart failure in the elderly. Presse Med 2013;42(6 Pt 1):995-1002.

39. Newton PJ, Davidson PM, Reid CM, et al. Acute heart failure admissions in New South Wales and the Australian Capital Territory: the NSW HF Snapshot Study. Med J Aust 2016;204(3):113.e1-8.

40. Friocourt P, Belmin J. Cardiovascular agents in the elderly: main rules to optimize their use. Rev Prat 2009;59(10):1370-6.

41. Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency department. Resuscitation 2007;73(1):96-102.

42. Messerli FH, Bangalore S, Yao SS, Steinberg JS. Cardioprotection with beta-blockers: myths, facts and Pascal’s wager. J Intern Med 2009;266: 232-41.

43. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62.

44. Herink M, Ito MK. Medication Induced Changes in Lipid and Lipoproteins. South Dartmouth (MA):, Inc.; 2015. Available at: Checked by 15.08.2016.

45. Khouri C, Jouve T, Blaise S, et al. Peripheral vasoconstriction induced by beta-blockers: a systematic review and a network meta-analysis. Br J Clin Pharmacol 2016;82(2):549-60.

46. Du Q, Sun Y, Ding N, et al. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One 2014;9(11):e113048.

47. Arnold SV, Spertus JA, Lipska KJ, et al. Type of β-blocker use among patients with versus without diabetes after myocardial infarction. Am Heart J 2014;168(3):273-279.e1.

48. Garcia-Egido A, Andrey JL, Puerto JL, et al. Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. Int J Clin Pract 2015;69(5):550-9.

49. Kotecha D, Manzano L, Krum H, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 2016;353:i1855.

50. Cioffi G1, De Feo S, Pulignano G, et al. Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol? Int J Cardiol 2006;107(2):220-4.

51. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2011;8(1):13-28.

52. Wehling M. Multimorbidity and polypharmacy: Which betablocker to use in relation to the pharmacokinetic profile and interaction potential. Arzneimittelforschung 2010;60(2):57-63.

53. Nozawa T, TaguchiM, TaharaK, et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol 2005;46:713-20

For citation:

Ushkalova E.A., Zyryanov S.K., Zatolochina K.E., Pereverzev A.P., Chukhareva N.A. Antiarrhythmic drugs use in elderly patients. Vaughan Williams class I and II drugs. Rational Pharmacotherapy in Cardiology. 2016;12(4):471-478. (In Russ.)

Views: 907

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)